Cancer and Blood Pressure Management, CARISMA Study

This phase II trial studies how well intensive blood pressure management works in decreasing
systolic blood pressure in patients with kidney or thyroid cancer that has spread to other
places in the body (metastatic) who are starting anti-angiogenic tyrosine kinase inhibitor
cancer therapy. This study is being done to find out if a systolic blood pressure to a target
of less than 120 mmHg (intensive systolic blood pressure management) can be achieved, well
tolerated, and beneficial as compared to the usual approach to a target of less than 140 mmHg
while taking an anti-angiogenic tyrosine kinase inhibitor. This study may help doctors
understand the best way to control blood pressure in kidney or thyroid cancer patients taking
anti-angiogenic tyrosine kinase inhibitor.

Intervention

Best Practice, Blood Pressure Measurement, Clinical Management, Quality-of-Life Assessment, Questionnaire Administration

Condition

Cardiovascular Disorder, Chronic Kidney Disease, Metastatic Renal Cell Carcinoma, Metastatic Thyroid Gland Medullary Carcinoma, Stage IV Renal Cell Cancer AJCC v8, Stage IV Thyroid Gland Medullary Carcinoma AJCC v8, Stage IVA Thyroid Gland Medullary Carcinoma AJCC v8, Stage IVB Thyroid Gland Medullary Carcinoma AJCC v8, Stage IVC Thyroid Gland Medullary Carcinoma AJCC v8

Investigators

Bonnie Ky

See list of participating sites